Aurobindo Pharma is reportedly planning to expand its footprint in newer markets in the European Union. The Hyderabad-based company intends to consolidate its position and presence among the top 10 companies in Europe.
The proposed expansion will not just be in new markets such as Poland and Czech Republic, but there will also be portfolio expansion through targeted first day launches in orals, hormonals, penems, oncology drugs and niche injectables, among others, according to the information shared in its latest investor presentation.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1871.55 |
| Dr. Reddys Labs. | 1346.25 |
| Cipla | 1456.25 |
| Zydus Lifesciences | 1099.65 |
| Lupin | 2398.70 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: